Hashad Yehia 4

What Happened

• Hashad Yehia, EVP of R&D and Chief Medical Officer of Bausch & Lomb Corporation, was granted 35,046 restricted stock units (RSUs) on 2026-02-25. The RSUs were granted at $0.00 (award), meaning they are compensation awards rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-25; filing date: 2026-02-27 (Form 4 filed two days after the grant).
• Transaction type/code: Award/Grant (A); acquisition price reported as $0.00.
• Shares granted: 35,046 RSUs. No post-transaction total beneficial ownership is specified in the filing.
• Footnote: The RSUs are granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan and are scheduled to vest one-third on each of the first three anniversaries of the grant date; vested RSUs are settled in common shares.
• No indication of a 10b5-1 plan, option exercise, sale, or tax-withholding settlement in this filing.

Context

• RSUs are a form of equity compensation: they convert into common shares only as they vest and generally depend on continued service (and any plan terms). This award is routine compensation for an executive and does not represent an immediate open-market purchase or sale.